Quiz|Articles|August 30, 2026

Dermatology Times Spot Test: August 30, 2026

Author(s)Marie Bosslett, Assistant Editor

Listen

0:00 / 0:00

Key Takeaways

A recurring quiz format is positioned as a rapid knowledge check on core dermatologic concepts and evolving clinical developments.
This week’s emphasis targets newsworthy dermatology updates from the prior week to reinforce immediacy and relevance.
Question submissions are invited from contributors, with direct outreach to editor Marie Bosslett at [email protected].

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Welcome to Dermatology Times' Spot Test!

Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest news from the last week.

Do you have a set of quiz questions to share? Contact editor Marie Bosslett at [email protected] to contribute.

What type of drug is imsidolimab, which just received orphan drug designation in the EU for GPP?

What was the primary endpoint of the phase 3 INTerpath-001 trial evaluating intismeran plus pembrolizumab?

Which proprietary technology is used in the manufacture of RHA Redensity Eye?